News / All News / Article

Protecting Health, Advancing Through Innovation: Weiming Penguin Team Invited to Visit Huanghai Pharmaceutical

Article images may contain Chinese text.

In summer in Jiao'ao, where mountains meet the sea, a delegation including Tian Ying, co-founder and president of Weiming Penguin, and Wei Yawei, general manager of DingTalk's healthcare industry business, was invited to visit Huanghai Pharmaceutical, a benchmark high-tech pharmaceutical enterprise contributing to Qingdao's development. They held extensive discussions with Huanghai Pharmaceutical Chair Liu Yajuan and the company's senior management team!
The visit to Huanghai Pharmaceutical aimed to jointly explore organizational effectiveness and new quality productive forces in the life sciences and healthcare sector in the new era. As a leading comprehensive enterprise specializing in pharmaceutical formulations in Qingdao, an Outstanding Enterprise in Management Innovation in Shandong Province, and a recipient of the Outstanding Social Responsibility Award for China's Pharmaceutical Industry, Huanghai follows the corporate purpose of “Making Medicines with Care, Benefiting Humanity.” Keeping pace with the times and focusing on innovative development are its top priorities. Both Weiming Penguin and Huanghai Pharmaceutical are high-tech enterprises. Through this collaboration, Weiming Penguin hopes to combine AI technology and its DIG intelligent digital solution portfolio with its accumulated experience serving more than 100 pharmaceutical enterprises, bringing fresh perspectives to Huanghai Pharmaceutical's innovative development and supporting its new journey toward digital and intelligent transformation.

These discussions were not only an important milestone in advancing both parties' sustainable development, but also established a new goal for their shared future growth. Connecting life sciences and healthcare, embracing an era of change. Looking ahead, we hope to fully leverage our respective strengths, enhance product research and development capabilities and market competitiveness, and guide the industry toward higher-quality, more sustainable development.
Qingdao Huanghai Pharmaceutical Co., Ltd., formerly Qingdao Huanghai Pharmaceutical Factory, was founded in 1959 and restructured as a privately owned company in 2004. It is a leading comprehensive enterprise specializing in pharmaceutical formulations in Qingdao, one of Qingdao's first high-tech enterprises, one of Qingdao's Top 100 Private Enterprises, an Outstanding Enterprise in Management Innovation in Shandong Province, a Contract-Honoring and Trustworthy Enterprise in Shandong Province, an AAA Credit-Rated Enterprise in Shandong Province, an Enterprise Making Outstanding Contributions to Shandong's Pharmaceutical Industry, one of China's Top 100 Pharmaceutical Manufacturing Enterprises by Tax Payments, and a recipient of the Outstanding Social Responsibility Award for China's Pharmaceutical Industry. Its trademark has been recognized as a China Well-Known Trademark.
The company will focus its future research and development on high-tech pharmaceutical formulations, exploring new areas in antihypertensive and blood glucose-lowering medicines, as well as treatments for hepatitis and cancer. Products currently under development mainly include cetirizine/pseudoephedrine extended-release capsules, candesartan cilexetil capsules, indapamide capsules, and lovastatin/niacin extended-release tablets.